Family Med Medical News about Dyslipidemias Xanthinol Niacinate Hypercholesterolemia Laropiprant

Become a Member Today!
Register

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Vascular Health and Risk Management, 11/03/09

Parhofer K – Niacin (nicotinic acid) is an effective drug which increases the plasma concentration of high–density lipoprotein (HDL)–cholesterol and decreases the concentration of low–density lipoprotein (LDL)–cholesterol, triglycerides and lipoprotein(a). Clinical studies indicate that niacin can significantly reduce the risk for cardiovascular events. However, niacin is not very commonly used because of significant side effects (especially flushing). Laropiprant is a potent selective antagonist of PGD2–receptor subtype–1 and can thus reduce niacin–induced flushing. Laropiprant does not change the effect of niacin on lipids or other side effects of niacin (ie, gastro–intestinal problems, glucose elevation). The combination of niacin with laropiprant may therefore enable use of niacin at higher doses and therefore exploit the full potential of the drug. Endpoint studies that will be published over the next few years will show whether this treatment modality also translates into clinical effect in patients treated with statins. Until publication of these studies niacin/laropiprant should be used only in high–risk patients not achieving lipid goals on statins.

<< Previous
Current status of maintenance therapy for advanced ovarian cancer

Next >>
Choosing the best treatments for acne

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09 Relevance Score: 64%

Study Demonstrates LIVALO Is an Efficacious Treatment for Achieving Lipid Goals
Internet Source, 10/23/09 Relevance Score: 64%

Self-Reported Adherence to Nonpharmacological Treatment and Association with Mortality over 6 Years: Population-Based Study in Older Persons with Hypercholesterolemia
Journal of the American Geriatrics Society, 10/28/09 Relevance Score: 44%

Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence
Current Medical Research and Opinion, 10/05/09 Relevance Score: 43%

U.S. Food and Drug Administration approves CRESTOR for use in pediatric patients with heterozygous familial hypercholesterolemia
AstraZeneca, 10/19/09 Relevance Score: 42%